Cg Oncology (CGON) Q2 Loss Widens 93%

Cg Oncology (NASDAQ:CGON), a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024. Revenue came in at zero, missing the $0.12 million revenue estimated by analysts and reflecting the absence of product sales ahead of commercialization. Quarterly operating costs rose sharply as the company increased investment in clinical trials and prepared for regulatory filings. Overall, the period was defined by accelerating expenses, no near-term revenue, but positive advances in both clinical and regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Cg Oncology is a biotechnology company developing targeted gene therapies for the treatment of bladder cancer, including high-risk, non-muscle invasive bladder cancer (NMIBC). Its lead experimental product is cretostimogene grenadenorepvec, a gene therapy delivered directly into the bladder to trigger cancer cell death while stimulating anti-tumor immune responses.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool